+357 96 030922
info@marketpublishers.com

Non-Injectable Insulin Market Forecasts to 2034 – Global Analysis By Product (Oral, Transdermal, Nasal, Sublingual and Other Products), Dosage, Distribution Channel and By Geography

https://marketpublishers.com/r/N1500770E824EN.html
Date: May 2026
Pages: 200
Price: US$ 4,150.00 (Single User License)
ID: N1500770E824EN

Abstracts

According to Stratistics MRC, the Global Non-Injectable Insulin Market is accounted for $2.1 billion in 2026 and is expected to reach $6.6 billion by 2034 growing at a CAGR of 15.2% during the forecast period. Non-injectable insulin refers to forms of insulin that do not require injection through a needle into the skin but instead can be administered through alternative methods. These techniques can be applied topically as patches or through inhalation, oral medication, or nasal sprays. With the introduction of non-injectable insulin, people who need insulin therapy will have more convenient options, which could lead to better treatment adherence and an overall improvement in quality of life.

According to Biocon, it terminated its phase 1 trial of oral Insulin Tregopil for Type 1 diabetes mellitus in June 2022, while continuing phase 3 trials for Type 2 diabetes mellitus

Market Dynamics:

Driver:

Technological developments in medicine delivery

The continuous progress in medication delivery technology is a major driver of the market's growth. The field of diabetes management is changing as a result of these innovative technical advancements, which make non-injectable insulin substitutes more

dependable, efficient, and appealing to patients and medical professionals alike. Furthermore, these developments have improved insulin dose accuracy and consistency, increasing the overall effectiveness of non-injectable insulin devices.

Restraint:

Side effects

Like any medication, non-injectable insulin can have side effects. Inhaled insulin might cause coughing or throat irritation. Oral insulin might interact with digestive enzymes or cause gastrointestinal issues. The reluctance of patients to embrace non-injectable insulin techniques presents a significant obstacle to the market's growth. Even with the obvious benefits and ease of use of non-injectable insulin alternatives, some people are reluctant to abandon the comfortable and well-recognized method of insulin injections.

Opportunity:

Rising diabetes prevalence

Alternative insulin administration systems are becoming more and more popular as diabetes becomes more commonplace worldwide. Non-injectable alternatives present a compelling substitute for diabetes individuals who may be uncomfortable with or struggle with injections. Increased adoption and market expansion are also facilitated by initiatives to inform patients, medical professionals, and the general public about the availability and advantages of non-injectable insulin solutions.

Threat:

High cost

If approved, non-injectable insulin may cost more than conventional injectable insulin. Expenses may rise as a result of R&D and technological advancements in delivery systems. Regulators have encountered difficulties with the development and approval of non-injectable insulin, though. Regulatory scrutiny and lengthy clinical trials are frequently necessary to ensure safety and efficacy for general use. The market's expansion is being hindered by these factors.

Covid-19 Impact:

The market for non-injectable insulin has been affected by the COVID-19 pandemic in a variety of ways. The initial interruption of the supply chain and limited accessibility to healthcare facilities notwithstanding, there was an increasing demand for creative solutions to treat diabetes. There was an increase in demand for non-injectable insulin options as patients looked for alternatives to lessen their hospital visits. In addition, the epidemic hastened the use of telemedicine, facilitating patient access to and discussion of these choices with medical professionals.

The sprays segment is expected to be the largest during the forecast period

The sprays segment is expected to be the largest during the forecast period due to its convenience and patient-friendly attributes. Patients looking for simpler and less unpleasant ways to manage their diabetes may find inhalable insulin sprays appealing as a less intrusive substitute for injections. Furthermore, these sprays guarantee accurate and efficient dosage due to notable developments in drug delivery technology.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period. Healthcare facilities play a pivotal role in the management and treatment of diabetes, rendering them notable hubs for the delivery of insulin products that are not injectable. Trust in non-injectable insulin alternatives is fostered by the clinical context of hospitals. A broad patient population can benefit from the promotion and provision of non-injectable insulin solutions by hospital pharmacy due to the confluence of these variables.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. High diabetes prevalence, a robust healthcare infrastructure, and a strong emphasis on research and innovation in the region contribute to its prominence. Notable are the patient's awareness and readiness to switch to non-injectable insulin substitutes. The region's significant market share is cemented by the high need for accessible and patient-focused diabetes treatment solutions.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The

+357 96 030922
info@marketpublishers.com

region's high diabetes prevalence, rapid urbanization, and expanding healthcare infrastructure have contributed to increased demand for innovative diabetes management solutions. Initiatives from the government and partnerships with pharmaceutical firms have further encouraged market expansion. Because of this, it is positioned as a significant player in the market thanks to its large and diverse patient population and encouraging healthcare programs.

Key players in the market

Some of the key players in Non-Injectable Insulin market include Generex Biotechnology Corp., Biodel, Inc., Oramed Pharmaceuticals, Inc., Diasome Pharmaceuticals, Inc., Midatech Pharma Plc, Shreya Life Sciences Pvt. Ltd., Boston Therapeutics, Inc., Diabetology Ltd., Emisphere Technologies, Inc., Coromed, Inc., Novo Nordisk, Sanofi, Eli Lilly, MannKind Corporation, Adocia, Oramed Pharmaceuticals, Dance Biopharm, Biocon and Janssen Pharmaceuticals.

Key Developments:

In November 2023, Eli Lilly and Company announced plans to construct a new $2.5 billion high-tech manufacturing site in Alzey, Rhineland-Palatinate, Germany. This new facility will further expand the company's global parenteral (injectable) product and device manufacturing network and support an increased demand for Lilly's medicines, including its diabetes and obesity portfolio.

In February 2022, Biocon made a significant move by acquiring Viatris' biosimilar portfolio for a substantial sum of USD 3.335 billion. This strategic acquisition bolstered Biocon's biosimilar product offerings and had a positive impact on the company's revenue generation.

Products Covered:

- Oral
- Transdermal
- Nasal
- Sublingual

Other Products

Dosages Covered:

Pills

Sprays

Distribution Channels Covered:

Hospital Pharmacies

Online Stores

Drug Stores

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

+357 96 030922
info@marketpublishers.com

- Spain
- Rest of Europe

Asia Pacific

- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific

South America

- Argentina
- Brazil
- Chile
- Rest of South America

Middle East & Africa

- Saudi Arabia
- UAE
- Qatar
- South Africa

Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Non-Injectable Insulin Market Forecasts to 2034 – Global Analysis By Product (Oral, Transdermal, Nasal, Sublingual and Other Products), Dosage, Distribution Channel and By Geography

Product link: https://marketpublishers.com/r/N1500770E824EN.html

Price: US$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/N1500770E824EN.html